The decrease in CD4, associated with a tendency towards an increase in CD8, led to a dramatic decrease in the CD4 to CD8 ratio, a result consistent with previous work demonstrating it represented a favorable prognosis marker for overall survival in vaccine-treated ovarian cancer patients [68]. The gene discussed is CD8A; the disease is ovarian carcinoma.